What to watch with Pharmakogenetik Medicheck and blood sugar?

When combining pharmacogenetics (e.g., Medicheck) with blood sugar monitoring, key points include: The Medicheck analyzes genetic variants affecting drug metabolism and response, including those relevant to glucose metabolism. From the context, rs1801282 (PPARG) is associated with insulin sensitivity and type 2 diabetes risk. Carriers of certain variants may have a higher risk of statin-induced blood sugar increases. Additionally, rs4149056 (SLCO1B1) influences statin myopathy risk, which can indirectly affect medication adherence and glycemic control. Important limitations: pharmacogenetic tests are not diagnostic for diabetes; their predictive power for individual blood sugar changes is modest. Always rely on clinical fasting glucose and HbA1c measurements. Discuss any medication adjustments with your physician. Also be aware that non-genetic factors (e.g., beta-blockers, thiazides, corticosteroids) can raise blood sugar. The Medicheck provides supportive information, not a standalone guide. Evidence level: human-moderate for PPARG-diabetes association; for Medicheck specifically, evidence is mixed/marketing.